



I hereby certify that this paper (along with any paper referred to as being attached
enclosed) is being deposited with the U.S. Postal Service on the date shown
below with sufficient postage as First Class Mail, in an envelope addressed to:
MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450.

Dated: 11/24/05 Signature: [Signature]
Genny Blumetell

IFW 1652
Docket No.: PROL-P01-040
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Reiss et al.

Application No.: 10/547,849

Confirmation No.: 1104

Filed: September 2, 2005

Art Unit: Not Yet Assigned

For: CBL-B POLYPEPTIDES, COMPLEXES
AND RELATED METHODS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as

defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. PROL-P01-040.

Dated: 11/22/06

Respectfully submitted,

By Anita Varma

Anita Varma

Registration No.: 43,221

FISH & NEAVE IP GROUP, ROPES & GRAY LLP


One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/547,849
				Filing Date	September 2, 2005
				First Named Inventor	Yuval Reiss
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	PROL-P01-040

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	BA	WO03/095971		11/20/03	Proteologics, Inc.		
	BB	WO03/078601		09/25/03	Proteologics, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	ALEXANDER et al., 1997, A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation, J. Virol. 71(8):6094-6099		
	CB	ARORA et al., 2000, Lentivirus Nef specifically activates Pak2, J. Virol. 74(23):11081-11087		
	CC	BACHMAIER et al., 2000, Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b, Nature 403:211-216		
	CD	BUSTELO et al., 1997, Cbl-b, a member of the Shc-1/c-Cbl protein family, inhibits Vav-mediated c-Jun N-terminal kinase activation, Oncogene 15:2511-2520		
	CE	CHIANG et al., 2000, Cbl-b regulates the CD28 dependence of T-cell activation, Nature 403:216-220		
	CF	ELLY et al, 1999, Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation, Oncogene 18:1147-1156		
	CG	ETTENBERG et al., 1999, cbl-b inhibits epidermal growth factor receptor signaling, Oncogene 18:1855-1866		
	CH	ETTENBERG et al., 2001, Cbl-b-dependent Coordinated Degradation of the Epidermal Growth Factor Receptor Signaling Complex, J. Biol. Chem. 276(29):27677-27684,		
	CI	FANG et al., 2001, Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells, J. Biol. Chem. 16:4872-4878		
	CJ	FUKUMORI et al., 2000, Regulation of cell cycle and apoptosis by human immunodeficiency virus type 1, Vpr. Microbes Infect. 2:1011-1017		
	CK	JOAZEIRO et al., 1999, The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase, Science 286:309-312		
	CL	LENARDO et al., 2002, Cytopathic killing of peripheral blood CD4 ⁺ T lymphocytes by human immunodeficiency virus type 1 appears necrotic rather than apoptotic and does not require env. J. Virol. 76:5082-5093		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/547,849
				Filing Date	September 2, 2005
				First Named Inventor	Yuval Reiss
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	PROL-P01-040

CM	LENG et al., 2002, Attenuated signaling associated with immune activation in HIV-1-infected individuals, Biochem. Biophys. Res. Comm. 298:464-467	
CN	MANNINEN et al., 2001, Activation of NFAT-dependent gene expression by Nef: conservation among divergent Nef alleles, dependence on SH3 binding and membrane association, and cooperation with protein kinase C- θ , J. Virol. 75:3034-3037	
CO	RENKEMA et al., 1999, Identification of the Nef-associated kinase as p21-activated kinase 2, Curr. Biol. 9(23):1407-1410	
CP	SCHNORR et al., 2001, Ras1 interacts with multiple new signaling and cytoskeletal loci in Drosophila eggshell patterning and morphogenesis, Genetics 159:609-622	
CQ	SCHUBERT et al., 1995, Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes, J. Virol. 69:7699-7711	
CR	SIMMONS et al., 2001, Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators, Immunity 14:763-777	
CS	TAPON et al., 1998, A new rac target POSH is an SH3-containing scaffold protein involved in the JNK and NF- κ B signalling pathways, EMBO J. 17(5):1395-1404	
CT	YOKOI et al., 2002, Cblb is a major susceptibility gene for rat type 1 diabetes mellitus, Nature Genet. 31:391-394	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/547,849

Attorney Docket No.: PROL-P01-040

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on 11/22/06
Date

Signature

Ginny Blundell

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (22 References) (2 pages)
References (22, BA-BB; CA-CT)